Clinical trial
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone…
NCT00219219 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219219 |
|---|---|
| Title | Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases |
| Official title | Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases |
| Lead sponsor | Novartis, Industry |
| Collaborators | Società Italiana di Urologia (SIU) |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Start date | Sep 1, 2003 |
| Completion | Oct 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 14, 2015 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: